Announced details
Treatment of achondroplasia (ACH). Research and development required for the application for marketing approval, including the Phase 3 clinical trial.
An incidence of approximately 1 in 25,000 newborns. A marked effect on height growth was confirmed in the Phase 2 clinical trial.
The Company received a notice of decision to award the grant. Capital and personnel relationships are not disclosed.
A national research and development agency responsible for administering the Grant Program for Research on Orphan Drugs and Other Products. Its location, representative, capital and year of establishment are not disclosed.
Orphan drug designation
Ministry of Health, Labour and Welfare (Minister of Health, Labour and Welfare)
¥17.730 million
The impact on results for the fiscal year ending March 2027 is expected to be immaterial.
The company does not address Offering price.
FY2026 Grant Program for Research on Orphan Drugs and Other Products administered by the National Institutes of Biomedical Innovation, Health and Nutrition
| Item | Details |
|---|---|
| Names of Products / Services Covered | umedaptanib pegol, RBM-007 |
| Counterparty | National Institutes of Biomedical Innovation, Health and Nutrition |
| Counterparty overview | A national research and development agency responsible for administering the Grant Program for Research on Orphan Drugs and Other Products. Its location, representative, capital and year of establishment are not disclosed. |
| Relationship with the Company | The Company received a notice of decision to award the grant. Capital and personnel relationships are not disclosed. |
| Contract Value | ¥17.730 million |
| Applicable area | Treatment of achondroplasia (ACH). Research and development required for the application for marketing approval, including the Phase 3 clinical trial. |
| Award/certification name | Orphan drug designation |
| Awarding / certifying body | Ministry of Health, Labour and Welfare (Minister of Health, Labour and Welfare) |
| Quantitative Effects | An incidence of approximately 1 in 25,000 newborns. A marked effect on height growth was confirmed in the Phase 2 clinical trial. |
| Impact on Business Performance | The impact on results for the fiscal year ending March 2027 is expected to be immaterial. |
| Source | FY2026 Grant Program for Research on Orphan Drugs and Other Products administered by the National Institutes of Biomedical Innovation, Health and Nutrition |
Items this document does not state (7)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The FY2026 research and development plan for this product, which has been designated as an orphan drug, was approved for grant funding following review as development of umedaptanib pegol progresses smoothly.